Lispi M

No ORCID on file · 11 papers in corpus · active 2020-2025

Study types

  • other 6
  • review 2

Condition tags

  • infertility 1
other 2025
Expert opinion on refined and extended key performance indicators for individualized ovarian stimulation for assisted reproductive technology
Fertility and sterility ·doi:10.1016/j.fertnstert.2024.10.001

OBJECTIVE: To assess the adequate ovarian follicular development and oocyte recovery between ovarian potential (antral follicle count [AFC]) before the start of ovarian stimulation (OS) and oocyte quantity and quality at oocyte retrieval. A…

other 2024
Dose accuracy of the follitropin alfa pen injector 2.0, the follitropin alfa:lutropin alfa 2:1 combination pen injector 2.0 and the choriogonadotropin alfa pen injector 1.0 used for fertility treatment
Expert opinion on drug delivery ·doi:10.1080/17425247.2024.2311127

BACKGROUND: This study aimed to confirm that the incremental dose/clicks system dispenses accurate doses for the Merck family of fertility pen injectors. RESEARCH DESIGN AND METHODS: Set doses (Vset) for three dose dial settings (minimum d…

other 2024
Effectiveness of recombinant human FSH: recombinant human LH combination treatment versus recombinant human FSH alone for assisted reproductive technology in women aged 35-40 years
Reproductive biomedicine online ·doi:10.1016/j.rbmo.2023.103725

RESEARCH QUESTION: According to real-world data, is recombinant human FSH (r-hFSH) combined with recombinant human LH (r-hLH) or r-hFSH alone more effective for women of advanced maternal age (AMA) in terms of live birth? DESIGN: Non-inter…

other 2023
Dosing Characteristics of Recombinant Human Luteinizing Hormone or Human Menopausal Gonadotrophin-Derived LH Activity in Patients Undergoing Ovarian Stimulation: A German Fertility Database Study
Gynecologic and obstetric investigation ·doi:10.1159/000530360

OBJECTIVES: The aim of the study was to evaluate dosing of recombinant human luteinizing hormone (r-hLH) or human menopausal gonadotrophin (hMG)-derived medications with LH activity in ovarian stimulation (OS) cycles for in vitro fertilizat…

review 2023
Effectiveness of recombinant human follicle-stimulating hormone (r-hFSH): recombinant human luteinizing hormone versus r-hFSH alone in assisted reproductive technology treatment cycles among women aged 35-40 years: A German database study
Best practice & research. Clinical obstetrics & gynaecology ·doi:10.1016/j.bpobgyn.2023.102350

This non-interventional study compared the effectiveness of recombinant human follicle-stimulating hormone (r-hFSH) and recombinant human luteinizing hormone (r-hLH) (2:1 ratio) versus r-hFSH alone for ovarian stimulation (OS) during assist…

other 2023
Letter to the editor in response to 'A real-world study of ART in France (REOLA) comparing a biosimilar rFSH against the originator according to rFSH starting dose' by P. Barrière, S. Hamamah, E. Arbo, C. Avril, B. Salle, J.-L. Pouly, et al. (J Gynecol Obstet Hum Reprod. 2023;52(1):102510)
Journal of gynecology obstetrics and human reproduction ·doi:10.1016/j.jogoh.2023.102640
review 2023
Treatment algorithms for high responders: What we can learn from randomized controlled trials, real-world data and models
Best practice & research. Clinical obstetrics & gynaecology ·doi:10.1016/j.bpobgyn.2022.102301

A high ovarian response to conventional ovarian stimulation (OS) is characterized by an increased number of follicles and/or oocytes compared with a normal response (10-15 oocytes retrieved). According to current definitions, a high respons…

other 2022
Cost-effectiveness analysis of recombinant human follicle-stimulating hormone alfa(r-hFSH) and urinary highly purified menopausal gonadotropin (hMG) based on data from a large German registry
Best practice & research. Clinical obstetrics & gynaecology ·doi:10.1016/j.bpobgyn.2022.02.002

This was a retrospective real-world evidence analysis of the costs per live birth for reference recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa) versus highly purified urinary human menopausal gonadotropin (hMG-HP), based o…

2022
Economic evaluation of Medically Assisted Reproduction: An educational overview of methods and applications for healthcare professionals.
Best practice & research. Clinical obstetrics & gynaecology ·doi:10.1016/j.bpobgyn.2022.01.008

Economic evaluations of the value-for-money of Medically Assisted Reproduction (MAR) interventions are increasingly important due to growing pressure on healthcare budgets. Although such evaluations are commonplace in the published literatu…

2021
Reduced FSH and LH action: implications for medically assisted reproduction.
Human reproduction (Oxford, England) ·doi:10.1093/humrep/deab065

Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) play complementary roles in follicle development and ovulation via a complex interaction in the hypothalamus, anterior pituitary gland, reproductive organs, and oocytes. Impair…

2020
Membrane Estrogen Receptor (GPER) and Follicle-Stimulating Hormone Receptor (FSHR) Heteromeric Complexes Promote Human Ovarian Follicle Survival.
iScience ·doi:10.1016/j.isci.2020.101812

Classically, follicle-stimulating hormone receptor (FSHR)-driven cAMP-mediated signaling boosts human ovarian follicle growth and oocyte maturation. However, contradicting in vitro data suggest a different view on physiological significance…